We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $104.5 · 2 analysts
Stored first · Google News · Yahoo Finance (English)
Long Path (MLAB) holds 8.6% of Mesa Laboratories, 477,126 shares - Stock Titan
Long Path (MLAB) holds 8.6% of Mesa Laboratories, 477,126 shares Stock Titan
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories Inc. (MLAB) Q1 2026 Earnings: Significant EPS Miss Sends Shares Lower - Revenue Per Share - dars.gov.et
Mesa Laboratories Inc. (MLAB) Q1 2026 Earnings: Significant EPS Miss Sends Shares Lower - Revenue Per Share dars.gov.et
Enterprise value to revenue forward of Mesa Laboratories, Inc. – NASDAQ:MLAB - TradingView
Enterprise value to revenue forward of Mesa Laboratories, Inc. – NASDAQ:MLAB TradingView
Mesa Laboratories, Inc. Actuals & Estimates (NASDAQ:MLAB) - TradingView
Mesa Laboratories, Inc. Actuals & Estimates (NASDAQ:MLAB) TradingView
Mesa Labs CAO Crennen sells $39,559 in MLAB shares By Investing.com - Investing.com Nigeria
Mesa Labs CAO Crennen sells $39,559 in MLAB shares By Investing.com Investing.com Nigeria
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | After market close (AMC) | $1.06 | — | — | $60.9M | — | Scheduled |
| FY2025 Q3 | 2024. 12. 31. | Time TBD | — | $0.94 | — | — | $178.84M | Reported |
| FY2025 Q2 | 2024. 09. 30. | Time TBD | — | $1.25 | — | — | $116M | Reported |
| FY2025 Q1 | 2024. 06. 30. | Time TBD | — | $0.62 | — | — | $58.17M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 02. 04. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2025. 12. 16. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2025. 08. 08. | Wells Fargo | — | Upgrade | Underweight → Equal-Weight | — | Wells Fargo: Underweight → Equal-Weight |
| 2025. 05. 30. | Wells Fargo | — | Maintain | Underweight → Underweight | — | Wells Fargo: Underweight |
| 2024. 10. 02. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2024. 08. 28. | Wells Fargo | — | Initiate coverage | — → Underweight | — | Wells Fargo: Underweight |
As of FY2025Q3 · Source: SEC/DART + price data
No holdings data to show.